Brain

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping SolutionViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling…

10 months ago
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured AneurysmsMicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms

MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms

MicroVention is Also Celebrating the Five-Year Anniversary of its WEB™ Aneurysm Embolization System with more than 10,000 Units Sold in…

10 months ago
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementAnnounces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals…

10 months ago
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

10 months ago
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X SyndromeSpinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel…

10 months ago
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm…

10 months ago
Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual MeetingRadical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting

Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting

Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market…

10 months ago
Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market InsightsDyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights

Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights

BURLINGAME, Calif., July 22, 2024 /PRNewswire/ -- The global Dyslexia Treatment Market is projected to grow from USD 7.59 billion…

10 months ago
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug ResistanceMIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance

New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /…

11 months ago
Zscale Labs™ Unveils Groundbreaking Neuromorphic AI for Medical ImagingZscale Labs™ Unveils Groundbreaking Neuromorphic AI for Medical Imaging

Zscale Labs™ Unveils Groundbreaking Neuromorphic AI for Medical Imaging

Cutting-Edge Technology Enhances Chest X-Ray Classification for Superior Patient Outcomes DUBAI, UAE, July 19, 2024 /PRNewswire/ -- Zscale Labs™ is excited…

11 months ago